tradingkey.logo
搜尋

Eli Lilly and Co

LLY
添加自選
1220.245USD
+37.085+3.13%
交易中 美東報價延遲15分鐘
1.15T總市值
43.27本益比TTM

關於 Eli Lilly and Co 公司

禮來公司是一家制藥公司。該公司在人類藥品領域發現、開發、製造和銷售產品。其糖尿病、肥胖症和其他心臟代謝產品包括 Basaglar、Humalog、Mounjaro、Trulicity 和 Zepbound。其腫瘤產品包括 Alimta、Retevmo、Tyvyt 和 Verzenio。其免疫學產品包括 Ebglyss、Olumiant、Omvoh 和 Taltz。其神經科學產品包括 Cymbalta 和 Emgality。其其他產品和療法包括 Cialis 和 Forteo。該公司通過位於美國(包括波多黎各)以及歐洲和亞洲的工廠生產和分銷其產品。該公司通過其子公司 POINT Biopharma Global Inc. 從事放射性藥物的發現、開發和製造,以及臨牀和臨牀前放射性配體療法。該公司還在開發用於治療炎症性腸病 (IBD) 的 α4β7 整合素口服小分子抑制劑 (稱爲 MORF-057)。

Eli Lilly and Co 簡介

公司代碼LLY
公司名稱Eli Lilly and Co
上市日期Jul 09, 1970
CEORicks (David A)
員工數量47000
證券類型Ordinary Share
年結日Jul 09
公司地址Lilly Corporate Ctr
城市INDIANAPOLIS
上市交易所NASDAQ OMX NASDAQ Basic NYSE
國家United States of America
郵編46285
電話13172762000
網址https://www.lilly.com/
公司代碼LLY
上市日期Jul 09, 1970
CEORicks (David A)

Eli Lilly and Co公司高管

名稱
名稱/職務
職務
持股
持股變動
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+11.64%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President and President - Lilly International
Executive Vice President and President - Lilly International
61.12K
+11.45%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President and President - Lilly International
Executive Vice President and President - Lilly International
61.12K
+11.45%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
55.56K
+53.81%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
55.56K
+53.81%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
46.10K
+13.81%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
46.10K
+13.81%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President and President - Lilly, USA and Global Customer Capabilities
Executive Vice President and President - Lilly, USA and Global Customer Capabilities
29.80K
-8.39%
Mr. Ilya Yuffa
Mr. Ilya Yuffa
Executive Vice President and President - Lilly, USA and Global Customer Capabilities
Executive Vice President and President - Lilly, USA and Global Customer Capabilities
29.80K
-8.39%
Mr. Diogo Rau
Mr. Diogo Rau
Executive Vice President, Chief Information and Digital Officer
Executive Vice President, Chief Information and Digital Officer
26.40K
+25.30%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Anne E. White
Ms. Anne E. White
Executive Vice President, President - Lilly Neuroscience
Executive Vice President, President - Lilly Neuroscience
74.21K
+11.64%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President and President - Lilly International
Executive Vice President and President - Lilly International
61.12K
+11.45%
Mr. Patrik Jonsson
Mr. Patrik Jonsson
Executive Vice President and President - Lilly International
Executive Vice President and President - Lilly International
61.12K
+11.45%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
55.56K
+53.81%
Ms. Anat Hakim
Ms. Anat Hakim
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
55.56K
+53.81%
Mr. Edgardo Hernandez
Mr. Edgardo Hernandez
Executive Vice President, President - Manufacturing Operations
Executive Vice President, President - Manufacturing Operations
46.10K
+13.81%

常見問題

Eli Lilly and Co的前五大股東是誰?

Eli Lilly and Co的前五大股東如下:Ms. Anne E. White

有多少機構持有Eli Lilly and Co(LLY)的股份?

截至2026Q1,共有6331家機構持有Eli Lilly and Co的股份,合計持有的股份價值約為864.16M,占公司總股份的91.72% 。與2025Q4相比,機構持股有所增加,增幅為69007266.00。

哪個業務部門對Eli Lilly and Co的收入貢獻最大?

在2026Q1,Diabetes-Mounjaro業務部門對Eli Lilly and Co的收入貢獻最大,創收6.52B,占總收入的37.02% 。
tradingkey.logo
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有